Patents by Inventor Markus Zwickl

Markus Zwickl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10918612
    Abstract: The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: February 16, 2021
    Inventor: Markus Zwickl
  • Publication number: 20160144464
    Abstract: A workpiece support for use in a machine tool for the purpose of placing flat workpieces in a machining station is provided. The flat workpiece is supported within a horizontal plane by supporting elements, and the supporting elements are arranged in at least two rows of supports. The rows of supports can be displaced along at least one axis of the horizontal plane.
    Type: Application
    Filed: June 23, 2014
    Publication date: May 26, 2016
    Inventor: Markus Zwickl
  • Publication number: 20140206674
    Abstract: The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 24, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Markus ZWICKL
  • Patent number: 5939531
    Abstract: The invention concerns recombinant antibodies directed to the extracellular domain of the human growth factor receptor c-erbB-2 comprising a light chain variable domain and a heavy chain variable domain of a monoclonal antibody, monoclonal antibodies directed to c-erbB-2 themselves, a method of manufacture of said recombinant antibodies and said monoclonal antibodies, hybridoma cells secreting said monoclonal antibodies, a method of manufacture of said hybridoma cells, DNA coding for the heavy chain variable domain, for the light chain variable domain and for the recombinant antibody, a method of manufacture of said DNA, hybrid vectors suitable for expression of said DNA, host cells transformed with said DNA, and the use of said recombinant antibodies and said monoclonal antibodies in the diagnosis and treatment of tumors.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 17, 1999
    Assignee: Novartis Corp.
    Inventors: Winfried Stephan Wels, Nancy E. Hynes, Ina-Maria Harwerth, Bernd Groner, Norman Hardman, Markus Zwickl
  • Patent number: 5571894
    Abstract: The invention concerns recombinant antibodies directed to the extracellular domain of the human growth factor receptor c-erbB-2 comprising a light chain variable domain and a heavy chain variable domain of a monoclonal antibody, monoclonal antibodies directed to c-erbB-2 themselves, a method of manufacturing those recombinant and monoclonal antibodies, hybridoma cells secreting those monoclonal antibodies, a method of manufacturing those hybridoma cells, DNAs encoding the heavy and light chain variable domains and the recombinant antibody, a method of manufacturing that DNA, hybrid vectors suitable for the expression of that DNA, host cells transformed with that DNA, and processes of using those recombinant and monoclonal antibodies in the diagnosis and treatment of tumors.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: November 5, 1996
    Assignee: Ciba-Geigy Corporation
    Inventors: Winfried S. Wels, Nancy E. Hynes, Ina-Maria Harweth, Bernd Groner, Norman Hardman, Markus Zwickl